The Oxford Science Park appoints Jitesh Patel as Development Manager

Oxford, UK, January 19 2022 - The Oxford Science Park, one of the UK's leading parks for science and technology companies, has appointed experienced property developer Jitesh Patel to the new role of Development Manager. He will play an important role in delivering the Park’s accelerated development schedule driven by last year’s strategic partnership between Magdalen College and GIC. Jitesh joins from Kajima Partnerships where he worked on a variety of projects valued in excess of £200m, including health care centres and housing. He has a MSc in Facilities Management and BSc in Building Surveying.

Magdalen College Oxford, owner of The Oxford Science Park, and an affiliate of GIC entered into the strategic partnership in October 2021 to accelerate the development of Park. The multi-building development plan at TOSP will accommodate strong demand and future growth requirements of leading science and technology companies. Several state-of-the-art facilities are planned for TOSP’s 23 gross acres of development land, with the capacity to add at least a further 500,000 sq ft.

‘The Oxford Science Park’s exciting and ambitious development plans will cement its position as a leading location for innovative science and technology companies. Having worked in Oxfordshire earlier in my career, I’m delighted to return to help TOSP deliver on this vision.’, Jitesh Patel, Development Manager at TOSP, commented on his appointment.

Rory Maw, CEO of The Oxford Science Park, said, ‘We are delighted to appoint Jitesh to the new role of Development Manager as the Park continues to evolve. His expertise in leading complex construction and property development projects make him the ideal addition to our enlarged team.’
 

 


More news and updates

Abzena launches EpiScreen® 2.0, a next-generation immunogenicity tool for de-risking the development of complex biologics

Abzena has announced the launch of its enhanced hashtag#bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical hashtag#immunogenicity in protein, antibody, and gene therapy therapeutics.

University of Oxford spin-out revealed as winner of ‘Golden Ticket’ programme for planetary health innovations

University of Oxford spin-out HydRegen has been revealed as the winner of a programme designed to recognise innovations in planetary health created by Pioneer Group in partnership with CPI.

CHAIN Biotech collaborates with German Cancer Research Center on development of a novel oncology vaccine

CHAIN Biotechnology Ltd and the German Cancer Research Center (DKFZ) have signed an agreement to collaborate on the development of therapeutic cancer vaccines for indications caused by Human Papillomavirus (HPV).

Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with positive pre-clinical data

Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer.

 

More within